Comprehensive analysis of the expression, prognostic, and immune infiltration for COL4s in stomach adenocarcinoma

Ying Xu ^1,2,3, Hangbin Jin ^1,2,3,4, Yan Chen ^1,2,3

¹Department of Gastroenterology, Affiliated Hangzhou First People's Hospital, Westlake University School of Medicine, Hangzhou, China.
²Hangzhou Institute of Digestive Diseases, Hangzhou, China.
³Key Laboratory of Integrated Traditional Chinese and Western Medicine for Biliary and Pancreatic Diseases of Zhejiang Province, Hangzhou, China.
⁴Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Hangzhou, Zhejiang, China.
⁵School of Life Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
⁶Department of Gastroenterology, Affiliated Hangzhou First People's Hospital, Westlake University School of Medicine, Hangzhou, China. zhangxiaofeng837@163.com.
⁷Hangzhou Institute of Digestive Diseases, Hangzhou, China. zhangxiaofeng837@163.com.
⁸Key Laboratory of Integrated Traditional Chinese and Western Medicine for Biliary and Pancreatic Diseases of Zhejiang Province, Hangzhou, China. zhangxiaofeng837@163.com.
⁹Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Hangzhou, Zhejiang, China. zhangxiaofeng837@163.com.
¹⁰Department of Gastroenterology, Affiliated Hangzhou First People's Hospital, Westlake University School of Medicine, Hangzhou, China. yjf-1976@163.com.
¹¹Hangzhou Institute of Digestive Diseases, Hangzhou, China. yjf-1976@163.com.
¹²Key Laboratory of Integrated Traditional Chinese and Western Medicine for Biliary and Pancreatic Diseases of Zhejiang Province, Hangzhou, China. yjf-1976@163.com.
¹³Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Hangzhou, Zhejiang, China. yjf-1976@163.com.
¹⁴Department of Gastroenterology, Affiliated Hangzhou First People's Hospital, Westlake University School of Medicine, Hangzhou, China. wangyu@zcmu.edu.cn.
¹⁵Hangzhou Institute of Digestive Diseases, Hangzhou, China. wangyu@zcmu.edu.cn.
¹⁶Key Laboratory of Integrated Traditional Chinese and Western Medicine for Biliary and Pancreatic Diseases of Zhejiang Province, Hangzhou, China. wangyu@zcmu.edu.cn.

⁰Department of Gastroenterology, Affiliated Hangzhou First People's Hospital, Westlake University School of Medicine, Hangzhou, China.

Bmc Medical Genomics +

|

June 21, 2024

View abstract on PubMed

Summary

Collagen type IV (COL4) gene expression is altered in stomach adenocarcinoma (STAD), with some forms upregulated and others downregulated. Upregulated COL4 genes correlate with poorer survival and increased immune cell infiltration, suggesting their potential as diagnostic and prognostic biomarkers for STAD.

Area Of Science

Oncology
Molecular Biology
Genomics

Background

Collagen genes, particularly COL4, are implicated in tumor invasion, metastasis, and extracellular matrix interactions.
Limited research exists on the diagnostic value of the COL4 family in stomach adenocarcinoma (STAD).

Purpose Of The Study

To investigate the diagnostic and prognostic value of the COL4 family in STAD.
To analyze the expression patterns and clinical significance of COL4 genes in STAD.

Main Methods

Utilized TCGA database for clinical and RNA sequencing data of STAD patients.
Performed differential expression analysis, Kaplan-Meier survival analysis, and Spearman correlation analysis.
Conducted gene set enrichment analysis (GSEA), immune infiltration analysis (TIMER), qPCR, and Western blot for validation.

Main Results

COL4A1/2 were upregulated, while COL4A5/6 were downregulated in STAD.
Upregulated COL4 genes correlated with poorer survival outcomes.
COL4A1/2/3/4 expression positively associated with immune cell infiltration and immunomodulatory molecules.

Conclusions

The COL4 family shows potential as diagnostic and prognostic biomarkers for STAD.
Altered COL4 expression impacts patient survival and the tumor microenvironment in STAD.

Keywords:

Biomarker COL4 Immune infiltration Prognosis Stomach adenocarcinoma

Related Concept Videos

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...